<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367638</url>
  </required_header>
  <id_info>
    <org_study_id>MG1111_P1</org_study_id>
    <nct_id>NCT02367638</nct_id>
  </id_info>
  <brief_title>Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults</brief_title>
  <official_title>A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether varicella live vaccine is safe and&#xD;
      effective in the healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the unsolicited adverse events during 42 days after vaccination</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Varicella (Chicken Pox)</condition>
  <arm_group>
    <arm_group_label>MG1111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VARIVAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG1111</intervention_name>
    <description>Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection</description>
    <arm_group_label>MG1111</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX</intervention_name>
    <description>VARIVAX is administered by subcutaneous injection</description>
    <arm_group_label>VARIVAX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female individuals between 20 and 55 years of age at screening test&#xD;
&#xD;
               -  In the case of female, individuals must be applicable for one of the following;&#xD;
&#xD;
               -  In the case of female of childbearing potential, any negative pregnancy test&#xD;
                  using urine hCG at screening&#xD;
&#xD;
               -  Menopausal for at least 2 years&#xD;
&#xD;
               -  Surgical sterilization (status after hysterectomy, bilateral oophorectomy,&#xD;
                  bilateral tubal ligation or the status using other contraceptive methods)&#xD;
&#xD;
               -  Monogamous relationship with vasectomized partner prior to screening visit&#xD;
&#xD;
               -  Individuals who are used acceptable contraceptive methods from 3 month prior to&#xD;
                  the subject's study entry to 1 month after vaccination (acceptable contraceptive&#xD;
                  methods; condom, diaphragm or cervical cap)&#xD;
&#xD;
          2. If male who is sexually active with the female &quot;of childbearing potential&quot; , the&#xD;
             individuals who agree to use any of the acceptable contraceptive methods during this&#xD;
             study period and agree to not donate the sperm until 1 month&#xD;
&#xD;
          3. At screening visits, individuals who are over 55 kg in man, over 50kg in woman and&#xD;
             whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)&#xD;
&#xD;
          4. Individual who has no clinically significant abnormalities in screening test within 28&#xD;
             days prior to vaccination&#xD;
&#xD;
          5. Individuals who were voluntarily signed informed consent form after receiving&#xD;
             education about this study and able to comply with the requirements for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals who received any other vaccines within 4 weeks prior to the screening&#xD;
             visit&#xD;
&#xD;
          2. Individuals who are planning to receive the other vaccines during this study&#xD;
&#xD;
          3. Individuals who had wound, scar, tattoo, dermatological disorders or injection&#xD;
             affecting safety evaluation&#xD;
&#xD;
          4. Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : &gt;5 cups/day,&#xD;
             alcohol : 210g/week, smoke : 10 /day)&#xD;
&#xD;
          5. Individuals who received any other investigational product within 90 days prior to&#xD;
             vaccination&#xD;
&#xD;
          6. individuals who donated the whole blood within 60 days or apheresis within 30 days&#xD;
             prior to vaccinating investigational product&#xD;
&#xD;
          7. Individuals who administered with another prescription medicine, herbal medicine&#xD;
             within 14 days or over-the-counter drug or vitamins within 7 days before vaccination&#xD;
&#xD;
          8. Individuals with history or illness affecting immune system (1) individuals with&#xD;
             continuously anti-viral therapy within 6 months prior to participating in this study&#xD;
             (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia&#xD;
             affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary&#xD;
             or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia,&#xD;
             dysgammaglobulinemia) (4) Individuals who are receiving immunosuppressive therapy (5)&#xD;
             Individuals who have treated immunoglobulin or blood-derived products within 6 months&#xD;
             of enrollment (6) Individuals with a family history of congenital or hereditary&#xD;
             immunodeficiency&#xD;
&#xD;
          9. Individuals with any clinically relevant history of other disease or disorder -&#xD;
             gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome),&#xD;
             psychiatric or malignant tumor&#xD;
&#xD;
         10. Individuals with any febrile illness or body temperature ≥38℃ before vaccination&#xD;
&#xD;
         11. Individuals known hypersensitivity or allergy to components of investigational product&#xD;
             (including gelatin and neomycin)&#xD;
&#xD;
         12. Individuals who are any clinically significant abnormality following the&#xD;
             investigator's review of the pre-study physical examination, ECG, and clinical&#xD;
             laboratory tests&#xD;
&#xD;
         13. Pregnancy or breastfeeding&#xD;
&#xD;
         14. Any other ineligible condition at the discretion of the investigator that would be&#xD;
             ineligible to participate the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

